Hyperpolarized 13C MR Imaging of Lactate in Patients With Locally Advanced Cervical Cancer (LACC) Cervical Cancer

• Status: Recruiting
• Trial end date: 2021-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to image tumour lactate in study participants with locally advanced cervical cancer. Our hypothesis is that lactate content in cervical tumours, as measured by hyperpolarized 13C Magnetic Resonance (MR) imaging, will correlate with diffusion-weighted MRI and 18FDG-PET (fluorodeoxyglucose-positron emission tomography). Furthermore, lactate imaging will potentially provide additional and more specific information regarding the metabolic activity of cervical tumours, thereby identifying regions of radiation resistance and guiding radiation treatment and brachytherapy.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sunnybrook Health Sciences Centre
• Collaborator: Ontario Institute for Cancer Research
• Treatments: Fluorodeoxyglucose F18

Criteria

Inclusion Criteria:

• Histologically confirmed squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the cervix, International Federation of Gynecology and Obstetrics (FIGO) stage IB-IVA

• Planned treatment with radical radiotherapy with or without concurrent cisplatin chemotherapy.

• Age ≥ 18 years.

Exclusion Criteria:

• Any anticancer treatment for their cervical cancer.

• Eastern Cooperative Oncology Group (ECOG) performance status > 2

• Other cervical cancer tumor histologies (e.g. small cell, serous)

• Contraindications to 18FDG PET-CT

• Inability to lie supine for 18FDG PET-CT

• Contraindication to radiotherapy (e.g. severe Crohn's disease)

• History of another invasive malignancy, except for non-melanoma skin cancer or tumors curatively treated with no evidence of disease for ≥ 5 years.

• Known pregnancy or lactating